At DevotedDOc , we recognize these hurdles and are committed to creating an inclusive telehealth experience that works for everyone regardless of socioeconomic status or location
Read on to learn more about the story of GLP-1 medication for weight loss, how it works, why it works, and what a well-informed path looks like
Schmidt & H
Proven alternatives deliver comparable results with established safety: tirzepatide monotherapy produces 15-22% weight loss with FDA approval and extensive clinical data, while CagriSema (cagrilintide + semaglutide) delivers 15-25% weight loss with Phase 3 trial validation and clearer path to medical acceptance
HydraStat is our patented delivery system that shrinks nutrient particles small enough to absorb through the soft tissue in your mouthbypassing the gut entirely
Tirzepatide is also a GLP-1 agonist, but adds a dual-action GIP Agonist which improves how well your body breaks down sugar and fat, while also reducing appetite and slowing digestion
